Sinphar PharmaceuticalLtd Balance Sheet Health
Financial Health criteria checks 6/6
Sinphar PharmaceuticalLtd has a total shareholder equity of NT$3.5B and total debt of NT$1.8B, which brings its debt-to-equity ratio to 52.3%. Its total assets and total liabilities are NT$6.3B and NT$2.8B respectively. Sinphar PharmaceuticalLtd's EBIT is NT$321.5M making its interest coverage ratio 14.9. It has cash and short-term investments of NT$1.2B.
Key information
52.3%
Debt to equity ratio
NT$1.82b
Debt
| Interest coverage ratio | 14.9x |
| Cash | NT$1.16b |
| Equity | NT$3.47b |
| Total liabilities | NT$2.79b |
| Total assets | NT$6.26b |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 1734's short term assets (NT$2.6B) exceed its short term liabilities (NT$1.1B).
Long Term Liabilities: 1734's short term assets (NT$2.6B) exceed its long term liabilities (NT$1.7B).
Debt to Equity History and Analysis
Debt Level: 1734's net debt to equity ratio (18.9%) is considered satisfactory.
Reducing Debt: 1734's debt to equity ratio has reduced from 62.3% to 52.3% over the past 5 years.
Debt Coverage: 1734's debt is well covered by operating cash flow (30.1%).
Interest Coverage: 1734's interest payments on its debt are well covered by EBIT (14.9x coverage).